Wockhardt Past Earnings Performance
Past criteria checks 0/6
Wockhardt's earnings have been declining at an average annual rate of -23.7%, while the Pharmaceuticals industry saw earnings growing at 13.9% annually. Revenues have been declining at an average rate of 6.8% per year.
Key information
-23.7%
Earnings growth rate
-16.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -6.8% |
| Return on equity | -15.5% |
| Net Margin | -18.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Wockhardt makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 27,760 | -5,010 | 6,170 | 0 |
| 30 Sep 23 | 27,740 | -5,140 | 6,150 | 0 |
| 30 Jun 23 | 27,000 | -6,260 | 6,120 | 0 |
| 31 Mar 23 | 26,510 | -5,590 | 6,380 | 0 |
| 31 Dec 22 | 26,280 | -6,100 | 7,050 | 0 |
| 30 Sep 22 | 27,820 | -5,210 | 7,530 | 0 |
| 30 Jun 22 | 29,650 | -2,980 | 7,680 | 0 |
| 31 Mar 22 | 32,300 | -2,440 | 7,509 | 0 |
| 31 Dec 21 | 32,074 | -787 | 7,596 | 0 |
| 30 Sep 21 | 31,175 | -567 | 7,637 | 0 |
| 30 Jun 21 | 29,696 | -867 | 7,829 | 0 |
| 31 Mar 21 | 27,080 | -2,990 | 7,930 | 0 |
| 31 Dec 20 | 27,633 | -1,780 | 8,041 | 0 |
| 30 Sep 20 | 24,910 | -2,583 | 7,154 | 0 |
| 30 Jun 20 | 27,167 | -3,181 | 7,700 | 0 |
| 31 Mar 20 | 28,440 | -1,638 | 7,704 | 0 |
| 31 Dec 19 | 35,136 | -1,320 | 9,513 | 0 |
| 30 Sep 19 | 36,903 | -2,127 | 9,884 | 0 |
| 30 Jun 19 | 40,138 | -1,533 | 10,275 | 0 |
| 31 Mar 19 | 35,658 | -2,897 | 8,943 | 0 |
| 31 Dec 18 | 41,851 | -3,346 | 10,574 | 0 |
| 30 Sep 18 | 41,445 | -3,043 | 10,409 | 0 |
| 30 Jun 18 | 40,536 | -2,848 | 9,424 | 0 |
| 31 Mar 18 | 39,245 | -6,083 | 10,293 | 0 |
| 31 Dec 17 | 37,822 | -6,285 | 10,261 | 0 |
| 30 Sep 17 | 37,724 | -6,416 | 10,444 | 0 |
| 30 Jun 17 | 38,148 | -6,213 | 9,537 | 0 |
| 31 Mar 17 | 39,664 | -1,957 | 10,542 | 0 |
| 31 Dec 16 | 41,695 | 485 | 10,395 | 0 |
| 30 Sep 16 | 42,485 | 1,745 | 10,392 | 0 |
| 30 Jun 16 | 44,134 | 2,499 | 10,446 | 0 |
| 31 Mar 16 | 44,532 | 2,507 | 10,387 | 0 |
| 31 Dec 15 | 46,085 | 3,168 | 15,201 | 194 |
| 30 Sep 15 | 49,148 | 6,031 | 14,960 | 194 |
| 30 Jun 15 | 45,497 | 4,992 | 8,914 | 0 |
| 31 Mar 15 | 44,815 | 4,049 | 9,442 | 0 |
| 31 Dec 14 | 43,867 | 4,452 | 13,521 | 181 |
| 30 Sep 14 | 42,410 | 4,024 | 13,332 | 181 |
| 30 Jun 14 | 44,632 | 5,374 | 7,976 | 0 |
| 31 Mar 14 | 48,304 | 8,407 | 13,899 | 181 |
| 31 Dec 13 | 52,772 | 11,010 | 12,610 | 0 |
| 30 Sep 13 | 54,759 | 12,244 | 12,367 | 0 |
| 30 Jun 13 | 56,264 | 15,358 | 12,147 | 0 |
Quality Earnings: 532300 is currently unprofitable.
Growing Profit Margin: 532300 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532300 is unprofitable, and losses have increased over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare 532300's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 532300 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 532300 has a negative Return on Equity (-15.5%), as it is currently unprofitable.